Coordinated prospective follow-up of Lynch syndrome is able to detect the majority of incident cancers.

Background: Lynch syndrome is one of the most common genetic predispositions to many cancers, most of which do not have a consensus recommendation for screening.

Aims: We studied in our region the value of a systematized and coordinated follow-up program for patients with Lynch syndrome on all organs at risk.

Methods: A multicenter prospective cohort evaluation was performed, from January 2016 to June 2021.

Pictorial review: Non-neoplastic soft-tissue masses.

As a tertiary centre for soft-tissue sarcomas, numerous non-neoplastic masses are referred to our institution. In many cases, review of the imaging allows a confident diagnosis to be made without the need for biopsy. Lesions include anomalous muscles and variants, muscle injury, haematoma, myositis ossificans, aneurysm, abscess, tumoral calcinosis, amyloidosis and elastofibroma.

Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta.

Human leucocyte antigen (HLA)-DO is a non-classical major histocompatibility complex class II molecule which modulates the function of HLA-DM and the loading of antigenic peptides on molecules such as HLA-DR. The bulk of HLA-DO associates with HLA-DM and this interaction is critical for HLA-DO egress from the endoplasmic reticulum. HLA-DM assists the early steps of HLA-DO maturation presumably through the stabilization of the interactions between the N-terminal regions of the alpha and beta chains.

Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing.

Although statins are widely prescribed as cholesterol-lowering drugs, a number of studies suggest that these compounds may have anabolic effects on bone. Our aim was to assess whether simvastatin affects the rate of fracture healing in humans. A prospective, double-blind, randomized controlled trial was performed.